RxDoctor Payments Data

Oluwatosin Thompson, MD

Neurology · Baltimore, MDNPI 1477965697

Payments from drug & device makers

$44,486in general payments, 2019–2025

Across 135 payments — averaging $329.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$17K
  • Lilly USA, LLC$16K
  • AbbVie$11K
  • Amgen$131
  • Biohaven Pharmaceuticals, Inc.$50
  • Argenx US, Inc.$48
  • plus $23 from 1 others

What the payments were for

  • Consulting fees$21,80049%
  • Speaking & faculty fees$9,20021%
  • Travel & lodging$10,77224%
  • Food & beverage$2,7156%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly8$17,327
Lilly USA, LLC52$15,559
AbbVie(2 entities)69$11,348
Amgen2$131
Biohaven Pharmaceuticals, Inc.1$50
Argenx US, Inc.2$48
Eisai Inc.1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,486 in reported general payments places this provider in the 80th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$26,140
Medicare patients
228
Services billed
338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe54$55,105
Emgality PenGalcanezumab-Gnlm22$16,644
UbrelvyUbrogepant12$14,890
Rivastigmine22$5,936
Lacosamide29$4,084
Levetiracetam42$1,319
Propranolol Hcl ErPropranolol Hcl28$1,300
Carbidopa-LevodopaCarbidopa/Levodopa36$1,197
Pregabalin32$1,005
Gabapentin57$778
Memantine Hcl13$492
Donepezil Hcl60$491
RizatriptanRizatriptan Benzoate27$451
Venlafaxine Hcl ErVenlafaxine Hcl19$396
Nortriptyline Hcl18$160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$11,348$14,89012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 442 neurology providers in Maryland.

Other neurology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →